Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Bolt Biotherapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 40
- −1 vs. Q1 2023
- Shares held
- 25.1M
- +1.77M (+7.6%) vs. Q1 2023
- Total value
- $32.1M
- −$320.5K (−1.0%) vs. Q1 2023
- New holders
- 4
- 9 more added
- Sold out
- 5
- 10 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Salem Investment Counselors Inc | 40 | $52 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 139 | $178 | 0.00% | −8−5.4% | Reduced |
| Wells Fargo & Company | 158 | $202 | 0.00% | +7+4.6% | Added |
| Northwestern Mutual Wealth Management Co | 400 | $512 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 628 | $804 | 0.00% | −11,152−94.7% | Reduced |
| Tower Research Capital LLC (TRC) | 652 | $835 | 0.00% | −3,320−83.6% | Reduced |
| Federated Hermes, Inc. | 3,274 | $4.19K | 0.00% | −465−12.4% | Reduced |
| Stifel Financial Corp | 12,264 | $15.7K | 0.00% | +12,264 | New |
| Bank of New York Mellon Corp | 12,578 | $16.1K | 0.00% | −51−0.4% | Reduced |
| XTX Topco Ltd | 13,309 | $17.0K | 0.00% | +13,309 | New |
| Prudential Financial Inc | 24,400 | $31.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 31,182 | $39.9K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 33,569 | $43.0K | 0.00% | −272,833−89.0% | Reduced |
| State Street Corp | 48,737 | $62.4K | 0.00% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 64,013 | $81.9K | 0.00% | +64,013 | New |
| FMR LLC | 79,196 | $101.4K | 0.00% | +763+1.0% | Added |
| Marquette Asset Management, LLC | 97,835 | $125.2K | 0.03% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 101,200 | $129.5K | 0.00% | +26,000+34.6% | Added |
| Millennium Management LLC | 113,989 | $145.9K | 0.00% | −131,422−53.6% | Reduced |
| Privium Fund Management (UK) Ltd | 116,516 | $148.0K | 0.12% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 128,646 | $164.7K | 0.00% | −60,660−32.0% | Reduced |
| Assenagon Asset Management S.A. | 158,289 | $202.6K | 0.00% | −67,527−29.9% | Reduced |
| Goldman Sachs Group Inc | 284,170 | $363.7K | 0.00% | +1,085+0.4% | Added |
| BlackRock Inc. | 287,891 | $368.5K | 0.00% | +13,461+4.9% | Added |
| Geode Capital Management, LLC | 352,219 | $450.8K | 0.00% | +174,227+97.9% | Added |
| Hawkeye Capital Management, LLC | 415,039 | $531.3K | 1.00% | 00.0% | Unchanged |
| Acuitas Investments, LLC | 460,385 | $589.3K | 0.34% | +460,385 | New |
| Renaissance Technologies LLC | 483,939 | $619.0K | 0.00% | +27,200+6.0% | Added |
| Adage Capital Partners GP, L.L.C. | 500,000 | $640.0K | 0.00% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 719,546 | $921.0K | 0.09% | 00.0% | Unchanged |
| Vanguard Group Inc | 928,276 | $1.19M | 0.00% | 00.0% | Unchanged |
| Newtyn Management, LLC | 1,000,000 | $1.28M | 0.30% | −115,110−10.3% | Reduced |
| Samsara BioCapital, LLC | 1,049,153 | $1.34M | 0.24% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 1,166,952 | $1.49M | 0.95% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,541,000 | $1.97M | 0.04% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,891,467 | $2.42M | 0.80% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 2,754,437 | $3.53M | 0.23% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,986,147 | $3.82M | 0.00% | +147,702+5.2% | Added |
| Tang Capital Management LLC | 3,333,803 | $4.27M | 0.63% | +1,706,250+104.8% | Added |
| Vivo Capital, LLC | 3,871,291 | $4.96M | 0.59% | 00.0% | Unchanged |
| Velan Capital Investment Management LP | 0 | $0 | 0.00% | −140,000−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −28,500−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −24,712−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −20,120−100.0% | Sold out |